Compact edge platform brings ISC’s AI software to the point of care on NVIDIA Jetson; first software device, CystoSmart™, cleared in Brazil and SingaporeISC 100 by CystoSmart running on the ISC 100: ...
The Brighterside of News on MSN
New molecular camera could revolutionize bladder cancer screening
MIT researchers created a nanosensor catheter that detects bladder cancer biomarkers far earlier than current tests.
The application for the next-generation mitomycin formulation is supported by 3-month complete response data from the phase 3 UTOPIA trial.
The global urinalysis market is valued at USD 4.2 billion in 2026 and is projected to reach USD 5.9 billion by 2031, growing at a CAGR of ...
Among patients with bacillus Calmette-Guérin (BCG)–unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) who achieved a complete response (CR) with nogapendekin alfa ...
The FDA has accepted for review a new drug application (NDA) for UGN-103, an investigational intravesical formulation of ...
The FDA expanded the indication for nogapendekin alfa inbakicept-pmln plus BCG to include adults with BCG-unresponsive, ...
The approval adds patients with high-grade papillary-only tumors, based on trial data showing a 62% complete response rate in ...
American Society for Radiation Oncology (ASTRO) published its first clinical practice guideline on radiation therapy for ...
FDA Approves Expanded Indication for Anktiva in BCG-Unresponsive NMIBC / Anktiva, BCG-unresponsive NMIBC, cancer, cancer care ...
FDA adds high-grade papillary-only bladder cancer to Anktiva's indication on Oct. 14, before ImmunityBio's Jan. 6, 2027 ...
Not everyone with kidney cancer will experience all of these symptoms. Only 10 percent to 15 percent of patients have the “ ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results